![](https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2022/04/20/aapharma_1.png)
- Anthem Inc (NYSE:ANTM) has reported Q1 FY22 adjusted EPS of $8.25, up 17.7% Y/Y, beating the consensus of $7.81.
- Operating revenue rose 18% to $37.9 billion, slightly beating the expectations of $37.42 billion, driven by higher premium revenue due to growth in Medicaid & Medicare, MMM & Paramount acquisitions, higher premium rates, and pharmacy product revenue related to IngenioRx.
- The benefit expense ratio was 86.1%, increasing 50 basis points versus the prior-year quarter.
- Operating cash flow was $2.5 billion, or 1.4x net income, increasing $36 million when compared year-over-year.
- Medical enrollment increased 7.5% Y/Y to 46.8 million members.
- Medical enrollment increased by 1.4 million lives, driven by organic growth in Commercial fee-based business, the acquisition of Paramount Advantage's Medicaid members in Ohio, and growth in Individual Medicare Advantage enrollment.
- On April 19, 2022, the company's board declared a second-quarter 2022 dividend of $1.28 per share, payable on June 24, 2022, to shareholders of record on June 10, 2022.
- FY22 Outlook: Anthem expects FY22 adjusted EPS of more than $28.40 versus prior guidance of $28.25.
- Price Action: ANTM shares are up 3.13% at $533.21 during the premarket session on the last check Wednesday.